Total Payments
$725.58
2024 Payments
$139.26
Companies
16
Transactions
41
Medicare Patients
3,222
Medicare Billing
$299,144
Payment Breakdown by Category
Food & Beverage$725.58 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $725.58 | 41 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $162.36 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $112.72 | 8 | $0 (2024) |
| Lilly USA, LLC | $84.66 | 5 | $0 (2023) |
| Medtronic, Inc. | $49.33 | 1 | $0 (2023) |
| PFIZER INC. | $41.09 | 2 | $0 (2021) |
| Novo Nordisk Inc | $40.07 | 2 | $0 (2024) |
| Dexcom, Inc. | $39.50 | 2 | $0 (2023) |
| Mylan Specialty L.P. | $34.74 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $30.77 | 2 | $0 (2022) |
| Alnylam Pharmaceuticals Inc. | $27.90 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $139.26 | 8 | Bayer Healthcare Pharmaceuticals Inc. ($48.91) |
| 2023 | $315.45 | 16 | Bayer Healthcare Pharmaceuticals Inc. ($101.63) |
| 2022 | $127.99 | 9 | AstraZeneca Pharmaceuticals LP ($37.88) |
| 2021 | $142.88 | 8 | PFIZER INC. ($41.09) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Cardio-renal | ||||||
| 04/15/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Diabetes | ||||||
| 04/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Cardio-renal | ||||||
| 03/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.89 | General |
| 02/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Diabetes | ||||||
| 02/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Cardio-renal | ||||||
| 01/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.90 | General |
| 12/05/2023 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: Genetic Disease | ||||||
| 11/28/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Cardio-renal | ||||||
| 11/20/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: Endocrinology | ||||||
| 11/07/2023 | Exeltis, USA Inc. | SLYND (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Oral Contraceptive | ||||||
| 11/06/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Diabetes | ||||||
| 10/24/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Cardio-renal | ||||||
| 10/04/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: Endocrinology | ||||||
| 09/22/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/24/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Cardio-renal | ||||||
| 07/17/2023 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $13.28 | General |
| Category: Insulin Pump | ||||||
| 07/11/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Cardio-renal | ||||||
| 06/09/2023 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $49.33 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 05/05/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Cardio-renal | ||||||
| 04/03/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/28/2023 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Urology | ||||||
| 01/04/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Cardio-renal | ||||||
| 10/03/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 934 | 1,771 | $206,589 | $81,371 |
| 2022 | 12 | 1,009 | 2,063 | $248,455 | $97,820 |
| 2021 | 13 | 1,143 | 2,406 | $256,930 | $111,162 |
| 2020 | 7 | 136 | 182 | $21,424 | $8,791 |
Total Patients
3,222
Total Services
6,422
Medicare Billing
$299,144
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 162 | 610 | $110,715 | $43,317 | 39.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 122 | 122 | $20,801 | $12,936 | 62.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 101 | 247 | $28,916 | $12,455 | 43.1% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 121 | 122 | $24,156 | $5,636 | 23.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 129 | 129 | $4,541 | $1,949 | 42.9% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 128 | 128 | $4,506 | $1,934 | 42.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 18 | 66 | $5,445 | $1,840 | 33.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 110 | 118 | $5,238 | $961.85 | 18.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 37 | $1,567 | $286.75 | 18.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 64 | $512.00 | $44.61 | 8.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 128 | $192.00 | $10.16 | 5.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 202 | 847 | $153,731 | $59,271 | 38.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 123 | 123 | $20,972 | $13,297 | 63.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 69 | 109 | $12,761 | $5,677 | 44.5% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2022 | 116 | 116 | $22,968 | $5,630 | 24.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 27 | 156 | $12,870 | $4,730 | 36.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 26 | 34 | $6,994 | $3,518 | 50.3% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 138 | 138 | $4,858 | $2,124 | 43.7% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 138 | 138 | $4,858 | $2,086 | 42.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 110 | 118 | $5,238 | $966.22 | 18.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 28 | 56 | $2,372 | $452.28 | 19.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 16 | 76 | $608.00 | $56.13 | 9.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 16 | 152 | $228.00 | $11.82 | 5.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 202 | 729 | $127,892 | $57,398 | 44.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 127 | 127 | $21,018 | $14,028 | 66.7% |
About Amanda Davis, NP
Amanda Davis, NP is a Family Medicine healthcare provider based in Willcox, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2020. The National Provider Identifier (NPI) number assigned to this provider is 1043850795.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amanda Davis, NP has received a total of $725.58 in payments from pharmaceutical and medical device companies, with $139.26 received in 2024. These payments were reported across 41 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($725.58).
As a Medicare-enrolled provider, Davis has provided services to 3,222 Medicare beneficiaries, totaling 6,422 services with total Medicare billing of $299,144. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Willcox, AZ
- Active Since 01/10/2020
- Last Updated 05/11/2020
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1043850795
Products in Payments
- Kerendia (Drug) $162.36
- FARXIGA (Drug) $58.26
- TRULICITY (Drug) $49.45
- INTERSTIM (Device) $49.33
- COLOGUARD DNA CAPTURE REAGENTS (Device) $41.09
- Dexcom G6 Transmitter (Medical Supply) $39.50
- MOUNJARO (Drug) $35.21
- Yupelri (Drug) $34.74
- GIVLAARI (Drug) $27.90
- Rybelsus (Drug) $24.04
- VOQUEZNA (Drug) $20.49
- Myrbetriq (Drug) $19.49
- Vascepa (Drug) $19.20
- ENTRESTO (Drug) $17.31
- SLYND (Drug) $17.14
- Ozempic (Drug) $16.03
- LEQVIO (Drug) $13.46
- Omnipod (Device) $13.28
- EVENITY (Biological) $12.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.